OSE Immunotherapeutics : Clinical catalysts to support 2024
>Five products at the clinical stage - The company gave an update on its clinical-stage products and our five main takeaways are as follows:Tedopi: the protocol for the second phase III trial in the second-line treatment of lung cancer needed for the product filing was accepted by the FDA mid-January. The trial could begin in Q2 2024 in the US and in H2 2024 in Europe. At the same time, the product is being evaluated in combination with other therapeutic agents...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.